| PFE |
Pfizer Inc. |
92%
|
Licensing Royalty and Other revenue of $97 million in the first quarter of 2026 included $30 million related to the Pfizer Matrix-M agreement signed in January 2026. |
| PFE |
Pfizer Inc. |
92%
|
Reciprocal relationship from PFE graph: Reciprocal relationship from NVAX graph: Licensing Royalty and Other revenue of $97 million in the first quarter of 2026 included $30 million related to the Pf… |
| PFIZER-INC |
PFIZER-INC |
92%
|
The License and Option Agreement provides a non-exclusive, worldwide, license, to the Company's Matrix-M TM adjuvant technology (the “Matrix-M Technology”) for Pfizer to research, develop, and commer… |
| SNYNF |
Sanofi |
92%
|
than all of the outstanding 2031 Notes unless at least $ million aggregate principal amount of 2031 Notes are outstanding and not called for redemption as of the time the Company sends the related re… |
| SNYNF |
Sanofi |
92%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYN… |
| SANOFI |
SANOFI |
90%
|
The Company is eligible to receive milestone payments totaling up to $ 350 million in the aggregate with respect to the COVID-19 Vaccine products, of which $ 75 million due upon completion of the tec… |
| SK-BIOSCIENCE |
SK-BIOSCIENCE |
90%
|
Other Partners include upfront payments, royalties and milestone revenue under licensing agreements including Takeda and SK bioscience. |
| TAKEDA |
TAKEDA |
90%
|
Other Partners include upfront payments, royalties and milestone revenue under licensing agreements including Takeda and SK bioscience. |
| AUSTRALIA |
AUSTRALIA |
85%
|
The Company has an APA with the Commonwealth of Australia (“Australia”) for the purchase of doses of COVID-19 Vaccine (the “Australia APA”). |
| TKPHF |
Takeda Pharmaceutical Company Limited |
85%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from TKPH… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
72%
|
our reputation, business, and financial results. The U.S. FDA and similar foreign governmental authorities have the authority to require the recall of certain vaccine candidates. Manufacturers may, u… |
| MRK |
Merck & Co., Inc. |
72%
|
our reputation, business, and financial results. The U.S. FDA and similar foreign governmental authorities have the authority to require the recall of certain vaccine candidates. Manufacturers may, u… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from MRK graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from MRK grap… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
including a $ million escrow funding. The Notice also acknowledged that such MOU is no longer feasible and that the related funds may be released to the Company. In March 2025, the Pharmaceutical Man… |
| BIOLOGICS-MANUFACTURING-CENTRE-INC |
BIOLOGICS-MANUFACTURING-CENTRE-INC |
62%
|
in funding investments related to building out and operating our manufacturing and distribution network, among other expenses, in support of our global supply commitment, and are applied to billings … |
| CO-LTD |
CO-LTD |
62%
|
ny also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a… |
| COMPANY-FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-UK-LIM |
COMPANY-FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-UK-LIM |
62%
|
ny also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a… |
| CSL-LTD-SANOFI-PASTEUR-SA-PFIZER-INC |
CSL-LTD-SANOFI-PASTEUR-SA-PFIZER-INC |
62%
|
our reputation, business, and financial results. The U.S. FDA and similar foreign governmental authorities have the authority to require the recall of certain vaccine candidates. Manufacturers may, u… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
ements for cross-border transfers of personal information and certain countries have also established specific legal requirements for data localization (such as where personal data must remain stored… |
| FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-TEXAS-LLC |
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-TEXAS-LLC |
62%
|
ny also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a… |
| FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-USA-INC |
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-USA-INC |
62%
|
ny also evaluated whether certain options outlined in the Sanofi Agreement represented material rights that would give rise to a performance obligation and concluded that none of the options convey a… |
| INDIA-PVT-LTD |
INDIA-PVT-LTD |
62%
|
s to drive value creation for its R&D assets early in the development process and for Matrix-M ™ adjuvant alone. The Company’s three strategic priorities are: focusing on its partnership with Sanofi … |
| NEW-YORK-MELLON-TRUST-COMPANY |
NEW-YORK-MELLON-TRUST-COMPANY |
62%
|
oduct thereafter, and royalty payments on Sanofi’s sales of all such licensed products. As of March 31, 2026, remaining Sanofi milestone payments of $425 million include $75 million related to COVID-… |
| SANOFI-PASTEUR-INC |
SANOFI-PASTEUR-INC |
62%
|
s to drive value creation for its R&D assets early in the development process and for Matrix-M ™ adjuvant alone. The Company’s three strategic priorities are: focusing on its partnership with Sanofi … |
| SERUM-LIFE-SCIENCES-LIMITED |
SERUM-LIFE-SCIENCES-LIMITED |
62%
|
s to drive value creation for its R&D assets early in the development process and for Matrix-M ™ adjuvant alone. The Company’s three strategic priorities are: focusing on its partnership with Sanofi … |
